Summary & Overview
HCPCS M1433: Oral Chemotherapy Exposure, 30-Day Window
HCPCS Level II code M1433 denotes documentation that a patient was on oral chemotherapy on or within 30 days before a denominator-eligible encounter. Nationally, this code is used in quality measurement and clinical documentation to capture exposure to oral antineoplastic agents, a growing component of cancer care as oral regimens expand treatment options outside traditional infusion settings. Accurate use of M1433 supports population-level tracking of oral chemotherapy utilization and informs care coordination between oncology teams, primary care, and pharmacy services.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose, the typical service settings where it is recorded, and what stakeholders can expect when reviewing claims and quality measure data tied to oral chemotherapy exposure. The publication also outlines benchmarking context, common documentation patterns, and relevant policy considerations for national reporting. Data not available in the input for specific modifier use, associated taxonomies, ICD-10 diagnoses, related codes, or service line detail is noted where applicable.
Billing Code Overview
HCPCS Level II code M1433 indicates a patient receiving oral chemotherapy on or within 30 days before the denominator-eligible encounter. This code documents current or recent use of oral antineoplastic therapy as part of a clinical or quality measure denominator.
-
Service type: Documentation of oral chemotherapy medication exposure
-
Typical site of service: Outpatient oncology clinic, infusion center follow-up visits, or ambulatory care encounters where medication history is reviewed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic colorectal cancer presents for an oncology clinic visit within 30 days of starting an oral chemotherapy agent (for example, capecitabine). The visit is a denominator-eligible encounter where clinicians review tolerance, side effects, adherence, and the need for laboratory monitoring. Typical workflow includes medication reconciliation, assessment of adverse effects, review of recent labs (CBC, CMP), documentation that the patient is on an oral cytotoxic or targeted agent, and counseling about administration and toxicity management. The service is reported to indicate the patient was receiving oral chemotherapy on or within 30 days before the eligible encounter. Typical site of service is an outpatient oncology clinic, infusion center intake visit (for oral therapy management), or physician office visit tied to cancer care coordination.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when a distinct E/M visit is performed in addition to services related to chemotherapy management during the same encounter |
59 | Distinct procedural service |